ライフサイエンスコーパス: LAM

1 LAM cells bear mutations in tuberous sclerosis (TSC) gen

2 LAM cells have biallelic loss of either tuberous scleros

3 LAM ELISA had the following sensitivity, specificity, po

4 LAM is a complex heteropolysaccharide synthesized by an

5 LAM is an elegant model of malignancy because biallelic

6 LAM is caused by mutations in the tuberous sclerosis com

7 LAM is caused by mutations in the tuberous sclerosis gen

8 LAM is characterized by neoplastic growth of smooth musc

9 LAM is typically caused by tuberous sclerosis complex 2

10 LAM LFA had a sensitivity of 50% for definite and probab

11 LAM LFA had a sensitivity of 68% for the composite stand

12 LAM LFA had a sensitivity of 75% for definite histopatho

13 LAM LFA in CSF is a useful additional diagnostic tool.

14 LAM lung nodules also produced OPG, as shown by expressi

15 LAM lung nodules showed reactivities to antibodies to tu

16 LAM monoprophylaxis was effective in preventing de novo

17 LAM pathogenic mechanisms mirror those of many forms of

18 LAM patients had significantly higher serum prostaglandi

19 LAM-HTGTS assays are sensitive, reproducible, relatively

20 LAM-HTGTS differs from related approaches because it det

21 Xpert tests improved case finding by 21.6%, LAM testing alone improved it by 13.5%, and dual Xpert t

22 Using a LAM patient-derived cell line (bearing biallelic Tuberin

23 down of GRAIL before LAM treatment abrogated LAM-induced hyporesponsiveness.

24 s and develop therapeutic strategies against LAM.

25 n-Pacific (APAC) (51 cases), Latin American (LAM) (348 cases), European (EU) (750 cases), and North A

26 Lysine 2,3-aminomutase (LAM) is a radical S-adenosyl-L-methionine (SAM) enzyme a

27 tes, but is not absolutely required for, AML/LAM cell growth and survival.

28 Among LAM recipients, 44% were HBV naive (HBsAb-/HBcAb-) at LT

29 001), while Beijing (OR, 0.6; P = 0.006) and LAM (OR, 0.7; P = 0.07) strains clustered less.

30 Interestingly, AG and LAM synthesis was restored in the mutant not only upon e

31 tion of the arabinose content of both AG and LAM that accompanied the accumulation of DPA in the muta

32 he buildup of the arabinan domains of AG and LAM.

33 AML and LAM are etiologically linked to mutations in the tsc2 an

34 logically slowing the progression of AML and LAM with rapamycin, our understanding of their pathogene

35 CNS involvement, renal and hepatic AMLs and LAM, even if clinical signs are not obvious.

36 TCMs enhanced IFN and LAM antiviral activities and improvements of liver funct

37 f HBsAg+ rate between infants in the LdT and LAM groups(1.9% vs. 3.7%; P=0.758).

38 LdT and LAM use in late pregnancy for highly viremic mothers was

39 nally, we investigated the ability of LM and LAM from C. glutamicum, and C. glutamicumDeltamptC and C

40 LM and LAM molecules produced by three different glycosyltransf

41 l established that the interaction of LM and LAM with TLR2 is a process dependent on the structure of

42 g alpha(1-->2)-Manp residues found in LM and LAM.

43 required for synthesis of full-length LM and LAM.

44 th both tuberous sclerosis complex (TSC) and LAM (TSC-LAM) into induced pluripotent stem cells (iPSC)

45 n used along with rapamycin, might attenuate LAM progression and potentially other TSC-related disord

46 ering RNA-mediated knockdown of GRAIL before LAM treatment abrogated LAM-induced hyporesponsiveness.

47 HLA types and disease caused by the Beijing, LAM, LCC, and Quebec strains.

48 Both LAM and hLM were recognized by dendritic cells, mainly v

49 ibition of human CD4(+) T cell activation by LAM also was associated with increased GRAIL expression.

50 Induction of CD4(+) T cell anergy by LAM may represent one mechanism by which M. tuberculosis

51 wth factors and matrix remodeling enzymes by LAM cells enables their access to lymphatic channels and

52 zation of L-alpha-lysine to L-beta-lysine by LAM, via the stable allylic anhydroadenosyl radical (anA

53 umor-suppressor genes (TSC1/TSC2) that cause LAM, a multisystem disease characterized by cystic lung

54 ign-appearing spindle and epithelioid cells (LAM cells) that express smooth-muscle and melanocyte-lin

55 Primary AML cells, LAM, and AML tissues expressed CCR3, CXCR4, CXCR6, and C

56 Combining LAM with AFB had an AUROC = 0.68 (95% CI 0.59-0.77), sig

57 alleles that were incapable of complementing LAM production in M. smegmatis were not viable in M. tub

58 as significantly associated with concomitant LAM therapy (adjusted hazard ratio [HR], 4.61; 95% confi

59 as expressed in type II pneumocytes covering LAM nodules and caused AML cell growth and protection fr

60 Cultured LAM cells retained surface expression of GD3 over severa

61 by the demonstrated sensitivity of cultured LAM cells to complement mediated cytotoxicity via GD3 an

62 Pregnancy appears to exacerbate LAM, suggesting that estrogen (E2) may play a role in th

63 oliferation of cells cultured from explanted LAM lungs, and selectively induced migration of LAM cell

64 ous population of cells grown from explanted LAM lungs.

65 may allow for a population of GD3-expressing LAM cells to expand within patients.

66 ogether these results reveal a new model for LAM pathogenesis in which activation of MEK-dependent pa

67 The arabinosyltransferase EmbC required for LAM biosynthesis is essential.

68 acidification may be potential therapies for LAM.

69 may be an effective combination therapy for LAM.

70 identified in exhaled breath condensate from LAM subjects and was increased by aspirin treatment, ind

71 mutations was a viable approach to generate LAM-like cells.

72 haMan-based Lipid A mimetics (alpha,alpha-GM-LAM) induced potent activation of NF-kappaB signaling in

73 In LAM cell-fibroblast co-cultures, acidification parallele

74 nti-OPG and anti-gp100 (HMB45) antibodies in LAM lung nodules.

75 of arabinan chains on the mannan backbone in LAM remain.

76 and nuclear localization in SM-like cells in LAM lungs and in TSC2-null xenographic tumors.

77 otein and protease activity were detected in LAM-associated fibroblasts but not the LAM cell line 621

78 and impact of dynamic hyperinflation (DH) in LAM.

79 nfirmed cathepsin K protein was expressed in LAM but not control lungs.

80 nic anhydrases, which were also expressed in LAM lung tissue.

81 ection of cells that resemble those found in LAM tumors by unbiased in vivo differentiation.

82 DH is frequent in LAM, even in patients with mild spirometric abnormalitie

83 itor, Rapamycin, stabilizes lung function in LAM and decreases the volume of renal angiomyolipomas, b

84 he overexpression of ganglioside D3 (GD3) in LAM.

85 The prevalence of DH was high in LAM (55%), even in patients with mild spirometric abnorm

86 Serum OPG was significantly higher in LAM patients than in normal volunteers.

87 ort increased levels of active Src kinase in LAM lungs and in TSC2(-/-) cells, caused by a reduction

88 e important causes of exercise limitation in LAM.

89 sizes, infiltrates, and destroys the lung in LAM arises from an unknown source and has an innocent hi

90 We identified Rapamycin-dependent miRNA in LAM patient angiomyolipoma-derived cells using two separ

91 gene expression was 40-fold overexpressed in LAM compared with control lung tissue (P </= 0.0001).

92 ts with dysregulation of the mTOR pathway in LAM and AML.

93 . tropicalis (17.0%) being more prominent in LAM.

94 rmful side reactions: this "free radical" in LAM is never free.

95 pecific organs and may play similar roles in LAM.

96 antibodies to GD3 may thus be therapeutic in LAM, and enhancement of existing NKT-cell infiltration m

97 andin pathways may have therapeutic value in LAM and TSC-related diseases, and possibly in other cond

98 VEGF-C-induced LAM cell proliferation was in part a result of autocrine

99 The NCgl1054 mutant lacked LAMs and was defective in the elongation of the major PI

100 Lamivudine (LAM) has been shown to prevent de novo hepatitis B virus

101 describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mo

102 ination with interferon (IFN) or lamivudine (LAM) versus IFN or LAM were included.

103 itis B patients with preexisting lamivudine (LAM) resistance (LAM-R) undergoing liver transplantation

104 % at month 36 (P < 0.001), while lamivudine (LAM) or emtricitabine (FTC) use remained steady (71.9%)

105 Of the 700 mothers enrolled, 648 (LdT/LAM/NTx=252/51/345) completed the 52-week study with 661

106 eted the 52-week study with 661 infants (LdT/LAM/NTx=257/52/352).

107 The study endpoints were the safety of LdT/LAM use and MTCT rates.

108 LF-LAM was positive in 19 of 21 patients without evidence o

109 the Determine TB-LAM lateral flow assay (LF-LAM) results among human immunodeficiency virus-infected

110 ated NTM disease may cause false-positive LF-LAM results.

111 rabinomannan (LAM) lateral flow assay (LFA), LAM enzyme-linked immunosorbent assay (ELISA), and Xpert

112 Lipoarabinomannan (LAM) is a structurally heterogeneous amphipathic lipogly

113 Lipoarabinomannan (LAM) is composed of a phosphatidylinositol anchor follow

114 IM), lipomannan (LM), and lipoarabinomannan (LAM) are essential components of the cell wall and plasm

115 Lipomannan (LM) and lipoarabinomannan (LAM) are key Corynebacterineae glycoconjugates that are

116 cans, lipomannan (LM) and lipoarabinomannan (LAM).

117 ed whether mannose-capped lipoarabinomannan (LAM)-induced inhibition of CD4(+) T cell activation resu

118 The glycolipid lipoarabinomannan (LAM) plays an important role in mediating host-bacteria

119 osis-specific glycolipid, lipoarabinomannan (LAM), a promising urinary biomarker for the detection an

120 inosylated glycopolymers, lipoarabinomannan (LAM) and arabinogalactan (AG).

121 nd pericardial fluid (PF) lipoarabinomannan (LAM) assays in tuberculous pericarditis (TBP).

122 mmunogenic polysaccharide lipoarabinomannan (LAM).

123 iagnostic accuracy of the lipoarabinomannan (LAM) lateral flow assay (LFA), LAM enzyme-linked immunos

124 orbent assay, and urinary lipoarabinomannan (LAM) by Alere Determine TB LAM assay.

125 Urinary lipoarabinomannan (LAM) detection is a promising approach for rapid diagnos

126 ght to determine if urine lipoarabinomannan (LAM) would improve diagnosis of pulmonary TB.

127 cs, urine Xpert and urine-lipoarabinomannan (LAM) combined identified 88% of TB blood-culture-positiv

128 of lipomannans (LM) and lipoarabinomannans (LAM) that are abundant components of the multilaminate c

129 the lipoprotein, LpqW, regulates PIM and LM/LAM biosynthesis in mycobacteria.

130 ene resulted in a complete loss of mature LM/LAM and the appearance of a truncated LM (t-LM).

131 ant with the NCgl2760 gene fully restored LM/LAM synthesis.

132 Lymphangioleiomyomatosis (LAM) is a destructive lung disease of women associated w

133 Lymphangioleiomyomatosis (LAM) is a disorder that affects women and is characteriz

134 Lymphangioleiomyomatosis (LAM) is a fatal lung disease associated with germline or

135 Lymphangioleiomyomatosis (LAM) is a potentially fatal lung disease characterized b

136 Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease affecting some

137 Lymphangioleiomyomatosis (LAM) is a progressive destructive neoplasm of the lung a

138 Lymphangioleiomyomatosis (LAM) is a progressive disease caused by accumulation of

139 Lymphangioleiomyomatosis (LAM) is a progressive neoplastic disorder that leads to

140 Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it

141 Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affect

142 Lymphangioleiomyomatosis (LAM) is a rare disease in which LAM cells and fibroblast

143 Lymphangioleiomyomatosis (LAM) is a rare progressive lung disease of women.

144 Lymphangioleiomyomatosis (LAM) is a rare, low-grade, metastasizing neoplasm that a

145 Lymphangioleiomyomatosis (LAM) is an interstitial lung disease characterized by in

146 Lymphangioleiomyomatosis (LAM) is an often fatal disease primarily affecting young

147 Lymphangioleiomyomatosis (LAM) is characterized by exercise performance impairment

148 Lymphangioleiomyomatosis (LAM), a multisystem disease of women, is manifest by the

149 rare lung disease, lymphangioleiomyomatosis (LAM), manifests as neoplastic growth of smooth-muscle (S

150 rs that develop in lymphangioleiomyomatosis (LAM) as a consequence of biallelic loss of TSC1 or TSC2

151 characteristics of lymphangioleiomyomatosis (LAM) and angiomyolipoma cells.

152 d proliferation of lymphangioleiomyomatosis (LAM) cells, abnormal smooth muscle-like cells with mutat

153 gical treatment of lymphangioleiomyomatosis (LAM) were recently published.

154 omas and pulmonary lymphangioleiomyomatosis (LAM), emerge later, placing adults with undiagnosed TSC

155 ) and in pulmonary lymphangioleiomyomatosis (LAM).

156 n TSC and sporadic lymphangioleiomyomatosis (LAM).

157 closely related to lymphangioleiomyomatosis (LAM).

158 iation of TSC with lymphangioleiomyomatosis (LAM) from sporadic LAM.

159 ddle of the mannan core is present in mature LAM and allow for an updated working model of the biosyn

160 use truncated alleles were unable to mediate LAM production in Mycobacterium smegmatis and were unabl

161 targeting the Latin American-Mediterranean (LAM) and Beijing lineages.

162 isease caused by accumulation of metastatic (LAM) cells in the lungs, lymphatics, and the tumor angio

163 From 160 culture-positive sputa, mixed LAM and non-LAM strains were detected in 4 sputa belongi

164 a set of 377 cultured isolates, 4 were mixed LAM and non-LAM.

165 All three RNA-binding motifs (LAM, RRM1, and RRM2) of La/SSB are required for efficien

166 60 culture-positive sputa, mixed LAM and non-LAM strains were detected in 4 sputa belonging to 2 (2.8

167 cultured isolates, 4 were mixed LAM and non-LAM.

168 in the biosynthesis of singular arabinans of LAM.

169 The observed behavior of LAM cells with respect to their infiltrative growth patt

170 Both the structure and the biosynthesis of LAM have been studied extensively.

171 isms underlying the metastatic capability of LAM cells remain poorly understood.

172 ns in the tsc2 and tsc1 genes in the case of LAM.

173 ed tomography of the chest characteristic of LAM, but who have no additional confirmatory features of

174 The combination of LAM and AFB was significantly better than AFB alone amon

175 wall and that the cellular concentration of LAM in M. smegmatis is selectively modulated with the gr

176 ecific questions related to the diagnosis of LAM and management of pneumothoraces in patients with LA

177 tions against making a clinical diagnosis of LAM on the basis of the high-resolution computed tomogra

178 have no additional confirmatory features of LAM (i.e., clinical, radiologic, or serologic), the guid

179 2) may play a role in the unique features of LAM.

180 olecule is a hypermannosylated (hLM) form of LAM.

181 d access to seven arabinomannan fragments of LAM (1-7).

182 romise the subsequent immunodetectability of LAM, and in 20 min, the tuberculosis biomarker was conce

183 D3 as a suitable target for immunotherapy of LAM.

184 number of viable bacteria was independent of LAM content and phenotype.

185 lungs, and selectively induced migration of LAM cells identified by the loss of heterozygosity for T

186 e, we generated a robust human cell model of LAM by reprogramming TSC2 mutation-bearing fibroblasts f

187 ped thus represent a novel cellular model of LAM that can advance our understanding of disease pathog

188 l mechanistic basis for the pathogenicity of LAM cells and they rationalize Src kinase as a novel the

189 els that accurately reflect the pathology of LAM have been challenging to develop.

190 working model of the biosynthetic pathway of LAM and LM.

191 However, the percentage of LAM cells expressing these melanosomal antigens is limit

192 The female predominance of LAM suggests that estradiol contributes to disease devel

193 nic CD4(+) T cells primed in the presence of LAM also exhibited decreased response upon restimulation

194 The presence of LAM during primary stimulation of P25 TCR-transgenic mur

195 -epi-lipoxin-A4 reduced the proliferation of LAM patient-derived cells in a dose-dependent manner.

196 anergic state persisted after the removal of LAM.

197 on of miRs may contribute to the response of LAM and TSC patients to Rapamycin therapy.

198 iR) signaling is involved in the response of LAM to mTORC1 inhibition is unknown.

199 Sensitivity of LAM increased significantly among participants with a lo

200 pletes the picture of how the active site of LAM from Clostridium subterminale SB4 "tames" the 5'-dAd

201 a novel therapeutic target for treatment of LAM and TSC.

202 endations for the diagnosis and treatment of LAM.

203 remarkable progress in the understanding of LAM and rapid translation of this knowledge to an effect

204 Accumulating evidence supports the view of LAM as a low-grade, destructive, metastasizing neoplasm.

205 st that cathepsin K activity is dependent on LAM cell-fibroblast interactions, and inhibitors of extr

206 ured isolates from both patients showed only LAM by PCR and spoligotyping.

207 1%) tested positive with Xpert (90, 9.3%) or LAM (34, 3.5%) assays.

208 beneficial effect when compared with IFN or LAM for CHB on antiviral activity as evidenced by the lo

209 eron (IFN) or lamivudine (LAM) versus IFN or LAM were included.

210 station week 28, the mothers received LdT or LAM until postpartum week 4 or no treatment (NTx).

211 ls were noted in mothers who received LdT or LAM versus NTx.

212 We performed LAM LFA (on unprepared and supernatant CSF after heating

213 Urinary and PF LAM assays have low sensitivity but high specificity for

214 For PF LAM strip tests, switching cut-points from grade 1 to 2

215 roved it by 13.5%, and dual Xpert tests plus LAM testing improved it by 32.4%.

216 Patients with positive LAM or Xpert MTB/RIF results were referred for tuberculo

217 transplantation in patients with preexisting LAM resistance HBV.

218 was biased toward patients having pulmonary LAM.

219 and functional characteristics of pulmonary LAM cells.

220 ogically confirmed TB patients, quantitative LAM detection results increased progressively with bacil

221 s, there was no difference in de novo rates: LAM 8% (5 of 62), adefovir 15% (5 of 33), tenofovir 0% (

222 e, 54 years; 70% male), of which 62 received LAM.

223 ith preexisting lamivudine (LAM) resistance (LAM-R) undergoing liver transplantation.

224 hepatitis B patients with preexisting rt204 LAM-R mutations or virological load refractory to LAM un

225 ughput genome-wide translocation sequencing (LAM-HTGTS) to map hundreds of thousands of RAG-initiated

226 ated high-throughput genome-wide sequencing (LAM-HTGTS) method for the detection of genome-wide 'prey

227 supernatant CSF after heating and spinning), LAM ELISA, and Xpert MTB/RIF on the CSF samples.

228 Sporadic LAM can develop in women without TSC, owing to somatic m

229 lymphangioleiomyomatosis (LAM) from sporadic LAM.

230 5 of 367) in the differentiation of sporadic LAM from TSC/LAM (P < .01).

231 he differentiation of patients with sporadic LAM from those with TSC/LAM.

232 T studies of 472 patients: 365 with sporadic LAM, 82 with TSC/LAM, and 25 with TSC.

233 and, like other members of this superfamily, LAM utilizes radical-generating machinery comprising SAM

234 Symptomatic LAM occurs almost exclusively in females after menarche,

235 e Longitudinal Assessment of Manic Symptoms (LAM) study.

236 ipoarabinomannan (LAM) by Alere Determine TB LAM assay.

237 ial lipoarabinomannan in urine (Determine TB LAM), and a molecular assay performed on a sputum sample

238 erformed urine LAM testing (Determine(TM) TB LAM, Alere).

239 ccuracy of a urine antigen test Determine TB-LAM Ag (Determine TB-LAM; Alere, Waltham, MA, USA) for s

240 Determine TB-LAM had highest sensitivity at low CD4 cell counts: 66.7

241 Determine TB-LAM is a simple, low-cost, alternative to existing diagn

242 We retrospectively reviewed the Determine TB-LAM lateral flow assay (LF-LAM) results among human immu

243 Determine TB-LAM test strips provided results within 30 min.

244 A; Alere, Waltham, MA, USA) and Determine TB-LAM test.

245 The diagnostic accuracy of Determine TB-LAM used alone or combined with sputum smear microscopy

246 tigen test Determine TB-LAM Ag (Determine TB-LAM; Alere, Waltham, MA, USA) for screening for HIV-asso

247 and a slightly better effect (P = 0.01) than LAM on the normalization of serum alanine aminotransfera

248 These results demonstrate that LAM upregulates GRAIL to induce anergy in Ag-reactive CD

249 We report here that LAM lesions and angiomyolipomas overexpress urokinase-ty

250 tuberculosis, supporting the hypothesis that LAM itself is essential in M. tuberculosis.

251 orm lung nodules and it is hypothesized that LAM nodule-derived proteases cause cyst formation and ti

252 lular fractions and spheroplasts showed that LAM and lipomannan (LM) were primarily found in a cell w

253 her, the results presented here suggest that LAM is primarily localized with the mycolic acids in the

254 in spheroplast preparations, suggesting that LAM and LM are primarily associated with the putative ou

255 The LAM content of the M. smegmatis cell wall was dramatical

256 cative of functional COX-2 expression in the LAM airway.

257 p was 2.6 years overall and 5.3 years in the LAM group.

258 of these studies significant changes in the LAM/LM content of the cell wall were noted relative to t

259 Intriguingly, the LAM-like features of these cells suggest that haploinsuf

260 ed in LAM-associated fibroblasts but not the LAM cell line 621-101.

261 ty and specify the site of metastasis of the LAM cell.

262 fer all features that define cancer upon the LAM cell-metabolic reprogramming and proliferative signa

263 Thus, LAM is as an elegant, monogenic model of neoplasia, defy

264 sufficiency at the TSC2 locus contributes to LAM pathology, and demonstrated that iPSC reprogramming

265 adulthood, 21 presented with symptoms due to LAM, 19 with renal angiomyolipomas, and 10 with seizures

266 nt in situ, enhanced NKT-cell recruitment to LAM lung was not observed.

267 mutations or virological load refractory to LAM undergoing liver transplantation were included, with

268 g NKT cells can be directly cytotoxic toward LAM lung lesions.

269 n-638 resulted in the synthesis of truncated LAM, which appeared to lack arabinose branching.

270 uberous sclerosis complex (TSC) and LAM (TSC-LAM) into induced pluripotent stem cells (iPSC), followe

271 and that Rheb is a potential target for TSC/LAM therapy.

272 the differentiation of sporadic LAM from TSC/LAM (P < .01).

273 y angiomyolipomas associated with TSC or TSC/LAM.

274 patients: 365 with sporadic LAM, 82 with TSC/LAM, and 25 with TSC.

275 tients with sporadic LAM from those with TSC/LAM.

276 ghlighting the need for better understanding LAM's molecular etiology.

277 (3) from 3.5% to 50% (p < 0.001) for urinary LAM ELISA; for urinary LAM strip test, grade 1 and 2 cut

278 < 0.001) for urinary LAM ELISA; for urinary LAM strip test, grade 1 and 2 cut-points performed simil

279 The sensitivity of urinary LAM is increased in HIV-infected patients with a CD4 </=

280 Urine LAM testing may be most beneficial among patients with f

281 Diagnostic sensitivities of urine LAM and sputum AFB were 42.1% (95% CI 29.1-55.9%) and 21

282 d mycobacterial culture, and performed urine LAM testing (Determine(TM) TB LAM, Alere).

283 ed HIV are target populations for whom urine LAM detection may be particularly useful.

284 er of positive tests from urine Xpert, urine LAM and MTB-blood-culture correlated with PCs (p < 0.001

285 Urine Xpert, urine LAM and TB-blood-culture positive patients clustered sim

286 ned directly from isolated genomic DNA using LAM-PCR and unidirectionally ligated to bridge adapters;

287 omyomatosis (LAM) is a rare disease in which LAM cells and fibroblasts form lung nodules and it is hy

288 noreactivity predominantly co-localized with LAM-associated fibroblasts.

289 Patients with LAM also performed a 6-minute walk test (6MWT).

290 the diagnosis and treatment of patients with LAM are provided.

291 the diagnosis and treatment of patients with LAM are provided.

292 Patients with LAM had higher baseline dyspnea, poorer quality of life,

293 Forty-two patients with LAM performed symptom-limited incremental cycle exercise

294 rial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomi

295 In patients with LAM, sirolimus stabilized lung function, reduced serum V

296 imus may be useful in selected patients with LAM.

297 in phase 1-2 trials involving patients with LAM.

298 ns and lymphangioleiomyomas in patients with LAM.

299 anagement of pneumothoraces in patients with LAM.

300 Women with LAM can also develop renal angiomyolipomas.